Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program
Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile lab training…
BeautyHealth Announces Leadership Transition
BeautyHealth Announces Leadership Transition The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced that Andrew Stanleick will depart the Company as President & Chief Executive Officer and relinquish his Board seat, effective November 19, 2023. Current BeautyHealth…
Vicarious Surgical Reports Third Quarter 2023 Financial Results
Vicarious Surgical Reports Third Quarter 2023 Financial Results Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical…
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for…
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update. The third…
Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first FDA approved renal denervation…
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,000 shares of common stock and 10,000 restricted stock units…
Oak Street Health Opens Fifth Primary Care Center in Indianapolis Area
Oak Street Health, a network of value-based primary care centers for adults on Medicare and the only primary care provider to carry the AARP name, is now welcoming patients at the new Fall Creek center at 711 E 38th St in Indianapolis. This is the 13th center…
Oak Street Health Opens New Primary Care Center in Sun City, Arizona
Oak Street Health, a network of value-based primary care centers for adults on Medicare and the only primary care provider to carry the AARP name, is now welcoming patients at the new Sun City center at 10705 W Peoria Ave in Sun City, Arizona. This…
Doximity Announces Fiscal 2024 Second Quarter Financial Results
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 second quarter ended September 30, 2023. “We’re proud to make medicine mobile, with another quarter of record engagement across our entire…
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Novartis today announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib – a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor – in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by…
Natrelle® Unveils New “For Every BODY” Campaign
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), embraces the immensely personal choice that patients experience when choosing breast surgery. The new Natrelle® campaign, “For Every BODY,” highlights patients and their diverse stories, leveraging new imagery and visual assets which can be seen at www.alookforeverybody.com.…